Physician profile
Bruce A Brown
NPI 1508927310
$12,491.14
in general payments reported to CMS, 2019-2025
32 companies · $3,825 in 2025
The $3,825 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $980 · 2020: $338 · 2021: $817 · 2022: $2,122 · 2023: $1,922 · 2024: $2,488 · 2025: $3,825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,234.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,750.17 | 2019-2025 | Clareon, Hydrus Microstent, Unity |
| Glaukos Corporation | $1,580.13 | 2019-2025 | Idosetr, Idose, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Sun Pharmaceutical Industries INC. | $864.66 | 2019-2025 | Cequa |
| Eyevance Pharmaceuticals LLC | $605.77 | 2022 | |
| Abbvie INC. | $437.46 | 2022-2025 | Durysta |
| Allergan, INC. | $397.94 | 2019-2022 | |
| Lumenis Be INC | $321.46 | 2025 | M22 |
| New World Medical,INC. | $321.24 | 2022-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Oyster Point Pharma, INC. | $295.68 | 2022-2025 | Tyrvaya |
| Dompe US, INC. | $278.23 | 2019-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $211.33 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $177.89 | 2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $162.01 | 2023-2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Harrow Eye, LLC | $149.94 | 2024 | Iheezo |
| Sight Sciences, INC. | $127.18 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $120.73 | 2023-2025 | Vyzulta, Miebo |
| Johnson & Johnson Vision Care, INC. | $115.20 | 2019 | |
| Ivantis, INC | $87.50 | 2020 | |
| Kala Pharmaceuticals, INC. | $77.64 | 2019 | |
| Amgen INC. | $75.48 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $62.98 | 2022-2025 | Acthar |
| Ocular Therapeutix, INC. | $46.72 | 2022-2025 | Dextenza |
| Shire North American Group INC | $34.38 | 2019 | |
| Nova Eye, INC. | $33.23 | 2024 | |
| Carl Zeiss Meditec USA, INC. | $33.07 | 2023 | Clarus |
| Carl Zeiss Meditec, INC. | $22.22 | 2019 | |
| Halozyme INC | $19.72 | 2023 | |
| Thea Pharma INC. | $18.18 | 2023 | |
| Quidel Corporation | $18.07 | 2023 | |
| Rxsight INC | $17.46 | 2022 | |
| Horizon Therapeutics Plc | $14.97 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.